Table 6

 ACR responses at 6–18 months in those who entered phase II (intention-to-treat)

Combination (n = 56)SASP (n = 55)MTX (n = 54)SASP OR (95% CI)p Value*MTX OR (95% CI)p Value*
ACR, American College of Rheumatology; MTX, methotrexate; SASP, sulfasalazine.
The ORs are found with the combination group as the reference level.
*Fisher’s exact text used.
ACR 20 response16 (29%)10 (18%)8 (15%)1.25 (0.56 to 2.79)0.682.01 (0.85 to 4.76)0.14
ACR 50 response6 (11%)3 (6%)4 (7%)1.43 (0.43 to 4.81)0.761.79 (0.49 to 6.49)0.53
ACR 70 response2 (4%)1 (2%)1 (2%)1.50 (0.24 to 9.34)1.003.00 (0.30 to 29.78)0.62